Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis
https://doi.org/10.4081/aiua.2022.2.252
Supplementary Files: 79
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background: Alpha-adrenoreceptor antagonists or alpha-blockers are used in the treatment of hypertension, in the therapy of benign prostatic hyperplasia and in medical expulsive treatment of ureteral stones. These agents may affect the sexual function, with differences between drugs within the same class, depending on their selectivity for receptor subtypes. The aim of this review was to analyze the effects of alpha-blockers on sexual function. Materials and methods: We conducted a systematic review and meta-analysis by searching PubMed, EMBASE and other databases for randomized controlled trials (RCTs) reporting sexual adverse effects in patients treated with alpha-blockers. Odds ratios for sexual dysfunction were calculated using random effects Mantel-Haenszel statistics. Results: Out of 608 records retrieved, 75 eligible RCTs were included in the meta-analysis. Compared with placebo, alphablockers were associated with increased odds of ejaculatory disorders both in patients with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH) (OR: 7.53, 95% CI: 3.77-15.02, Z = 5.73, p < 0.00001, I2 = 55%) and in patients with ureteral stones (OR: 2.88, 95% CI: 1.50-5.44, Z = 3.19, p < 0.001, I2 = 31%). Uroselective alpha-blockers showed higher odds of ejaculatory disorders. Conversely, nonselective alpha-blockers were not associated with higher odds of ejaculatory dysfunction. Silodosin was associated with increased odds of ejaculatory dysfunction compared with tamsulosin (OR: 3.52, 95% CI: 2.18-5.68, 15 series, 1512 participants, Z = 5.15, p < 0.00001, I2 = 0%). Naftopidil and alfuzosin showed lower odds of ejaculatory dysfunction compared to uroselective alpha-blockers.No statistically significant differences in the odds of erectile dysfunction were observed when alpha-blockers were compared to placebo.
Frishman WH, Kotob F. Alpha-adrenergic blocking drugs in clinical medicine. J Clin Pharmacol. 1999; 39:7-16. DOI: https://doi.org/10.1177/00912709922007516
Civantos Calzada B, Aleixandre de Artiñano A. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001; 44:195-208. DOI: https://doi.org/10.1006/phrs.2001.0857
Graham RM. Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents. Am J Cardiol. 1984; 53:16A-20A. DOI: https://doi.org/10.1016/0002-9149(84)90829-4
Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2012; (8):CD004643. DOI: https://doi.org/10.1002/14651858.CD004643.pub3
Lepor H. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. Urol Clin North Am. 2016; 43:311-23.
Ishihama H, Momota Y, Yanase H, et al. Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol. 2006; 175:358-64. DOI: https://doi.org/10.1097/00005392-200601000-00121
Hwang EC, Gandhi S, Jung JH, et al. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2018; 10:CD007360. DOI: https://doi.org/10.1002/14651858.CD007360.pub3
Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6:e1000097. DOI: https://doi.org/10.1371/journal.pmed.1000097
Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366:l4898. DOI: https://doi.org/10.1136/bmj.l4898
Chapple CR, Al-Shukri SH, Gattegno B, et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a placebo and active comparator controlled phase 3a study Eur Urol. (Supplements) 2005;4:33-44. DOI: https://doi.org/10.1016/j.eursup.2004.10.010
Chapple CR, Montorsi F, Tammela TL, et al. European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011; 59:342-52. DOI: https://doi.org/10.1016/j.eururo.2010.10.046
Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010; 76:1446-1450. DOI: https://doi.org/10.1016/j.urology.2010.03.015
Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006; 98:1019-24. DOI: https://doi.org/10.1111/j.1464-410X.2006.06448.x
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998; 51:892-900. DOI: https://doi.org/10.1016/S0090-4295(98)00126-5
Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013; 189(1 Suppl):S122-8. DOI: https://doi.org/10.1016/j.juro.2012.11.020
Mehik A, Alas P, Nickel JC, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology. 2003; 62:425-9. DOI: https://doi.org/10.1016/S0090-4295(03)00466-7
Mohanty NK, Nayak RL, Malhotra V, Arora RP. A double-blind placebo controlled study of tamsulosin in the management of benign prostatic hyperplasia in an Indian population. Ann College of Surgeons of Hong Kong. 2003; 7:88-93. DOI: https://doi.org/10.1046/j.1442-2034.2003.00181.x
Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011; 14:143-8. DOI: https://doi.org/10.1038/pcan.2010.46
Singh P, Singh A, Indurkar M, Raj B. Efficacy and safety of tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. Asian Journal of Pharmaceutical and Clinical Research 2012; 5(Suppl 4):87-91.
Al-Ansari A, Al-Naimi A, Alobaidy A, et al. Efficacy of tamsulosin in the management of lower ureteral stones: a randomized double-blind placebo-controlled study of 100 patients Urology. 2010;75:4-7. DOI: https://doi.org/10.1016/j.urology.2009.09.073
Meltzer AC, Burrows PK, Wolfson AB, et al. Effect of tamsulosin on passage of symptomatic ureteral stones: A randomized clinical trial JAMA Intern Med. 2018; 178:1051-1057. DOI: https://doi.org/10.1001/jamainternmed.2018.2259
Singh I, Tripathy S, Agrawal V. Efficacy of tamsulosin hydrochloride in relieving "double-J ureteral stent-related morbidity": a randomized placebo controlled clinical study. Int Urol Nephrol. 2014; 46:2279-83. DOI: https://doi.org/10.1007/s11255-014-0825-8
Sur RL, Shore N, L'Esperance J, et al. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, doubleblinded, placebo-controlled trial. Eur Urol. 2015; 67:959-64. DOI: https://doi.org/10.1016/j.eururo.2014.10.049
Ye Z, Zeng G, Yang H, et al. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2018; 73:385-391. DOI: https://doi.org/10.1016/j.eururo.2017.10.033
Cho HJ, Shin SC, Seo DY, et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi Korean J Urol. 2013; 54:106-110. DOI: https://doi.org/10.4111/kju.2013.54.2.106
El Said NO, El Wakeel L, Kamal KM, Morad Ael R. Alfuzosin treatment improves the rate and time for stone expulsion in patients with distal uretral stones: a prospective randomized controlled study. Pharmacotherapy. 2015; 35:470-6. DOI: https://doi.org/10.1002/phar.1593
Ferre RM, Wasielewski JN, Strout TD, Perron AD. Tamsulosin for ureteral stones in the emergency department: a randomized, controlled trial. Ann Emerg Med. 2009; 54:432-9, 439.e1-2. DOI: https://doi.org/10.1016/j.annemergmed.2008.12.026
Itoh Y, Okada A, Yasui T, et al. Efficacy of selective alpha1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011; 18:672-4. DOI: https://doi.org/10.1111/j.1442-2042.2011.02810.x
Moursy E, Gamal WM, Abuzeid A. Tamsulosin as an expulsive therapy for steinstrasse after extracorporeal shock wave lithotripsy: a randomized controlled study. Scand J Urol Nephrol. 2010; 44:315-9. DOI: https://doi.org/10.3109/00365599.2010.494616
Naja V, Agarwal MM, Mandal AK, et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology. 2008; 72:1006-11. DOI: https://doi.org/10.1016/j.urology.2008.05.035
Resim S, Ekerbicer HC, Ciftci A. Role of tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy. Urology. 2005; 66:945-8. DOI: https://doi.org/10.1016/j.urology.2005.05.029
Chung JH, Oh CY, Kim JH, et al. Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. Curr Med Res Opin. 2018; 34:1793-1801. DOI: https://doi.org/10.1080/03007995.2018.1447451
Höfner K, Claes H, De Reijke TM, et al. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36:335-41. DOI: https://doi.org/10.1159/000019996
Kirby RS, Roehrborn C, Boyle P, et al. Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003; 61:119-26. DOI: https://doi.org/10.1016/S0090-4295(02)02114-3
Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005; 95:1006-12. DOI: https://doi.org/10.1111/j.1464-410X.2005.05456.x
Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2001; 58:953-9. DOI: https://doi.org/10.1016/S0090-4295(01)01448-0
Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003; 92:257-61. DOI: https://doi.org/10.1046/j.1464-410X.2003.04309.x
Roehrborn C.G. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2-year placebo-controlled study BJU Int. 2006; 97:734-741. DOI: https://doi.org/10.1111/j.1464-410X.2006.06110.x
Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res. 2007; 19:480-5. DOI: https://doi.org/10.1038/sj.ijir.3901554
Safarinejad MR. Safety and efficacy of tamsulosin in the treatment of painful ejaculation: a randomized, double-blind, placebocontrolled study. Int J Impot Res. 2006; 18:527-33. DOI: https://doi.org/10.1038/sj.ijir.3901466
Becker AJ, Stief CG, Machtens S, et al. Oral phentolamine as treatment for erectile dysfunction. J Urol. 1998; 159:1214-6. DOI: https://doi.org/10.1016/S0022-5347(01)63559-6
Choppin A, Blue DR, Hegde SS, et al. Evaluation of oral ro70- 0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. Int J Impot Res. 2001; 13:157-61. DOI: https://doi.org/10.1038/sj.ijir.3900653
Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial Prostate Cancer Prostatic Dis. 2007; 10:155-159. DOI: https://doi.org/10.1038/sj.pcan.4500925
Shelbaia A, Elsaied WM, Elghamrawy H, et al. Effect of selective alpha-blocker tamsulosin on erectile function in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2013; 82:130-5. DOI: https://doi.org/10.1016/j.urology.2013.03.026
van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000; 37:306-13. DOI: https://doi.org/10.1159/000052361
Agrawal M, Gupta M, Gupta A, et al. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. Urology. 2009; 73:706-9. DOI: https://doi.org/10.1016/j.urology.2008.11.013
Agrawal MS, Yadav A, Yadav H, et al. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol. 2009; 25:474-478. DOI: https://doi.org/10.4103/0970-1591.57917
Ahmed A.-F.A.-M., Al-sayed A.-Y.S. Tamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: Prospective, randomized, comparative study. Korean J Urol. 2010; 51:193-197. DOI: https://doi.org/10.4111/kju.2010.51.3.193
Dell'Atti L. Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. Urologia. 2015; 82:54-7. DOI: https://doi.org/10.5301/uro.5000083
De Nunzio C, Brassetti A, Bellangino M, et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: A short-term follow-up randomized, placebocontrolled study J Endourol. 2016; 30: 817-821. DOI: https://doi.org/10.1089/end.2016.0113
Elgalaly H, Sakr A, Fawzi A, et al. Silodosin vs tamsulosin in the management of distal ureteric stones: A prospective randomised study.Arab J Urol. 2016; 14:12-17. DOI: https://doi.org/10.1016/j.aju.2015.11.004
Georgescu D, Ionita-Radu F, Multescu R, et al. The role of alpha1-blockers in the medical expulsive therapy for ureteral calculi - a prospective controlled randomized study comparing tamsulosin and silodosin. Farmacia 2015; 63:184-188.
Gharib T, Mohey A, Fathi A, et al. Comparative study between silodosin and tamsulosin in expectant therapy of distal ureteral stones. Urol Int. 2018; 101:161-166. DOI: https://doi.org/10.1159/000490623
Gupta S, Lodh B, Kaku Singh A, et al. Comparing the efficacy of tamsulosin and silodosin in the medical expulsion therapy for ureteral calculi. J Clin Diagn Res. 2013; 7:1672-1674. DOI: https://doi.org/10.7860/JCDR/2013/6141.3241
Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006; 176:1529-33.
Ibrahim AK, Mahmood IH, Mahmood NS. Efficacy and safety of tamsulosin vs. alfuzosin as medical expulsive therapy for ureteric stones. Arab J Urol. 2013 11:142-147. DOI: https://doi.org/10.1016/j.aju.2013.02.003
Karadag E, Öner S, Budak YU, Atahan O. Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. Int Urol Nephrol. 2011; 43:949-954. DOI: https://doi.org/10.1007/s11255-011-9949-2
Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int. 2003; 91:41-4. DOI: https://doi.org/10.1046/j.1464-410X.2003.03077.x
Kumar S, Kurdia KC, Ganesamoni R, et al. Randomized controlled trial to compare the safety and efficacy of naftopidil and tamsulosin as medical expulsive therapy in combination with prednisolone for distal ureteral stones. Korean J Urol. 2013; 54:311-315. DOI: https://doi.org/10.4111/kju.2013.54.5.311
Manohar CMS, Nagabhushana M, Karthikeyan VS, et al. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial. Cent European J Urol. 2017; 70:148-153. DOI: https://doi.org/10.5173/ceju.2016.924
Masumori N, Tsukamoto T, Iwasawa A, et al. Hokkaido Urological Disorders Conference Writing Group. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urol Int. 2009; 83:49-54. DOI: https://doi.org/10.1159/000224868
Miyakita H, Yokoyama E, Onodera Y, et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2010; 17:869-875. DOI: https://doi.org/10.1111/j.1442-2042.2010.02614.x
Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: A randomized, open-label trial. The Journal of Applied Research 2005; 5:237-245.
Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial Indian J Pharmacol 2014; 46: 601-607. DOI: https://doi.org/10.4103/0253-7613.144912
Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study Cent European J Urol. 2017; 70:259-263.
Pompeo AC, Rosenblatt C, Bertero E, et al. Doxazosin and Tamsulosin Study Investigator Group. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int J Clin Pract. 2006; 60:1172-7. DOI: https://doi.org/10.1111/j.1742-1241.2006.01107.x
Samli MM, Dincel C.Terazosin and doxazosin in the treatment of BPH: Results of a randomized study with crossover in non-responders. Urol Int. 2004; 73:125-129. DOI: https://doi.org/10.1159/000079692
Shirakawa T, Haraguchi T, Shigemura K, et al. Silodosin versus naftopidil in japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized multicenter study. International J Urol. 2013; 20:903-910. DOI: https://doi.org/10.1111/iju.12055
Takahashi S, Yamaguchi K. Treatment of benign prostatic hyperplasia and aging: Impacts of alpha-1 blockers on sexual function. Journal of Men's Health. 2011; 8 (Suppl 1):S25-S28. DOI: https://doi.org/10.1016/S1875-6867(11)60015-8
Takeshita H, Moriyama S, Arai Y, et al. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Low Urin Tract Symptoms. 2016; 8:38-43. DOI: https://doi.org/10.1111/luts.12106
Watanabe T, Ozono S, Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res. 2011; 39:129-142. DOI: https://doi.org/10.1177/147323001103900105
Yamaguchi K, Aoki Y, Yoshikawa T, et al. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. Int J Urol. 2013; 20:1234-8. DOI: https://doi.org/10.1111/iju.12160
Yokoyama T, Hara R, Fukumoto K, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011; 18:225-30. DOI: https://doi.org/10.1111/j.1442-2042.2010.02708.x
Yokoyama T, Hara R, Fujii T, et al. Comparison of Two Different alpha1-Adrenoceptor Antagonists, Tamsulosin and Silodosin, in the Treatment of Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective Randomized Crossover Study LUTS: Lower Urinary Tract Symptoms 2012; 4:14-18. DOI: https://doi.org/10.1111/j.1757-5672.2011.00099.x
Yu HJ, Lin AT, Yang SS, et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int. 2011; 108:1843-8. DOI: https://doi.org/10.1111/j.1464-410X.2011.10233.x
Zaytoun OM, Yakoubi R, Zahran ARM, et al. Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: Randomized controlled trial. Urological Research. 2012; 40:327-332. DOI: https://doi.org/10.1007/s00240-011-0410-x
Keten T, Aslan Y, Balci M, et al. Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia Urology. 2015; 85:189-194. DOI: https://doi.org/10.1016/j.urology.2014.10.004
Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. 2005; 95:103-9. DOI: https://doi.org/10.1111/j.1464-410X.2004.05252.x
Choo MS, Song M, Kim JH, et al. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double blind, randomized, parallel, multicenter study. Urology. 2014; 83:875-81. DOI: https://doi.org/10.1016/j.urology.2013.11.013
Seki N, Takahashi R, Yamaguchi A, et al. Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study. Int J Urol. 2015; 22:311-6. DOI: https://doi.org/10.1111/iju.12680
Kim JJ, Han DH, Sung HH, et al. Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial. Int J Urol. 2014; 21:677-82. DOI: https://doi.org/10.1111/iju.12412
Lojanapiwat B, Kochakarn W, Suparatchatpan N, Lertwuttichaikul K. Effectiveness of low-dose and standard dose tamsulosin in the treatment of distal ureteric stones: a randomized controlled study. J Int Med Res. 2008; 36:529-36. DOI: https://doi.org/10.1177/147323000803600318
Yanardag H, Goktas S, Kibar Y, et al. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol. 2005;173:155-7. DOI: https://doi.org/10.1097/01.ju.0000146699.17331.19
Hareendran A, Abraham L. Using a treatment satisfaction measure in an early trial to inform the evaluation of a new treatment for benign prostatic hyperplasia. Value Health. 2005; 8(Suppl 1):S35-40. DOI: https://doi.org/10.1111/j.1524-4733.2005.00074.x
Lepor H. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. Urol Clin North Am. 2016; 43:311-23. DOI: https://doi.org/10.1016/j.ucl.2016.04.009
Nickel JC, Sander S, Moon TD. A meta-analysis of the vascularrelated safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008; 62:1547-59. DOI: https://doi.org/10.1111/j.1742-1241.2008.01880.x
Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016; 355:i6112. DOI: https://doi.org/10.1136/bmj.i6112
Sentürk AB, Aydin C, Ekici M, et al. Comparison of three most frequently used alpha blocker agents in medical expulsive therapy for distal ureteral calculi, result of a retrospective observational study. Arch Ital Urol Androl. 2018; 90:25-28. DOI: https://doi.org/10.4081/aiua.2018.1.25
Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97 (Suppl 2):34-8; discussion 44-5. DOI: https://doi.org/10.1111/j.1464-410X.2006.06104.x
Hisasue S, Furuya R, Itoh N, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006; 13:1311-6. DOI: https://doi.org/10.1111/j.1442-2042.2006.01535.x
Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med. 2008; 5:2185-90. DOI: https://doi.org/10.1111/j.1743-6109.2008.00779.x
Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006; 176:1529-1533. DOI: https://doi.org/10.1016/j.juro.2006.06.004
Yeung HEL, Sena SJ, Calopedos RJ, Woo HH. Alfuzosin and its effect on ejaculatory dysfunction: a systematic review. World J Mens Health. 2021; 39:186-194 DOI: https://doi.org/10.5534/wjmh.180024
Britto-Júnior J, Ribeiro A, Ximenes L, et al. Alpha1-adrenergic antagonists block 6-nitrodopamine contractions on the rat isolated epididymal vas deferens. Eur J Pharmacol. 2022; 915:174716. DOI: https://doi.org/10.1016/j.ejphar.2021.174716
Blum MD, Bahnson RR, Porter TN, Carter MF. Effect of local alpha-adrenergic blockade on human penile erection. J Urol. 1985; 134:479-481. DOI: https://doi.org/10.1016/S0022-5347(17)47248-X
Brindley GS. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol. 1986; 87:495-500. DOI: https://doi.org/10.1111/j.1476-5381.1986.tb10191.x
Marconi M, Pavez P, San Francisco I, Narvaez P. Priapism induced by use of tamsulosin: A case report and review of the literature. Arch Ital Urol Androl. 2019; 91:193. DOI: https://doi.org/10.4081/aiua.2019.3.193
Rampin O. Pharmacology of alpha-adrenoceptors in male sexual function. Eur Urol. 1999; 36 Suppl 1:103-6. DOI: https://doi.org/10.1159/000052329
van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)- adrenoceptor antagonists on male sexual function. Drugs. 2006; 66:287-301. DOI: https://doi.org/10.2165/00003495-200666030-00002
Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007; 51:1717-1723. DOI: https://doi.org/10.1016/j.eururo.2007.01.033
Yan H, Zong H, Cui Y, et al. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Sex Med. 2014; 11:1539-45. DOI: https://doi.org/10.1111/jsm.12499
Kallidonis P, Adamou C, Kotsiris D, et al. Young Academic Urologists of the European Association of Urology-Endourology Working Party. Combination therapy with alpha-blocker and phosphodiesterase-5 inhibitor for improving lower urinary tract symptoms and erectile dysfunction in comparison with monotherapy: a systematic
review and meta-analysis. Eur Urol Focus. 2020; 6:537-558. DOI: https://doi.org/10.1017/9781108913638.022
Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc. 2015;13:196-207. DOI: https://doi.org/10.1097/XEB.0000000000000065
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
